Studies have revealed that TGF-β has also been shown to suppresses the function of antigen-specific CTLs in the priming and effector phases in vitro and may contribute to reduce CD8+ T cell proliferation in the tumor invasive front [72]. The gene discussed is CD8A; the disease is neoplasm.